What is VNDA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.28B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for VNDA?

P/E (TTM) is n/a and 52-week range is $4.27 to $9.94 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s VNDA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for VNDA?

The company profile lists revenue (TTM) near $215M, net income (TTM) near $-27.45B, EPS (TTM) near $-4.63 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Vanda Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Washington, Washington Dc, US, 60.1M shares outstanding, ISIN US9216591084 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Vanda Pharmaceuticals Inc

$VNDA

Health Care · Biotechnology

IR Run Scenarios

$4.57

+0.88%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The company is headquartered in Washington, Washington Dc and currently employs 533 full-time employees. The company went IPO on 2006-04-12. The firm's commercial portfolio consist of four products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome, PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease , and NEREUS for the prevention of vomiting induced by motion. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.

Employees

533

Website

www.vandapharma.com/

IPO

2006-04-12

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)